Polaris Group (6550.TW)

TWD 33.3

(9.9%)

Long Term Debt Summary of Polaris Group

  • Polaris Group's latest annual long term debt in 2023 was 352.96 Million TWD , up 1044.22% from previous year.
  • Polaris Group's latest quarterly long term debt in 2024 Q2 was 1.66 Billion TWD , up 51.71% from previous quarter.
  • Polaris Group reported annual long term debt of 30.84 Million TWD in 2022, down -73.69% from previous year.
  • Polaris Group reported annual long term debt of 117.26 Million TWD in 2021, down -7.08% from previous year.
  • Polaris Group reported quarterly long term debt of 968.73 Million TWD for 2024 Q1, up 174.45% from previous quarter.
  • Polaris Group reported quarterly long term debt of 352.96 Million TWD for 2023 Q4, up 30.05% from previous quarter.

Annual Long Term Debt Chart of Polaris Group (2023 - 2016)

Historical Annual Long Term Debt of Polaris Group (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 352.96 Million TWD 1044.22%
2022 30.84 Million TWD -73.69%
2021 117.26 Million TWD -7.08%
2020 126.19 Million TWD -37.63%
2019 202.34 Million TWD -3.73%
2018 210.18 Million TWD -70.63%
2017 715.59 Million TWD 0.16%
2016 714.43 Million TWD 0.0%

Peer Long Term Debt Comparison of Polaris Group

Name Long Term Debt Long Term Debt Difference
Apex Biotechnology Corp. 116.19 Million TWD -203.77%
Sinphar Pharmaceutical Co.,Ltd. 1.49 Billion TWD 76.376%
Panion & Bf Biotech Inc. 125.41 Million TWD -181.434%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 700 Million TWD 49.576%
GenMont Biotech Incorporation 20.11 Million TWD -1655.017%
Abnova (Taiwan) Corporation 2.6 Million TWD -13470.511%
Adimmune Corporation 1.91 Billion TWD 81.597%
Tanvex BioPharma, Inc. 1.56 Billion TWD 77.494%
Energenesis Biomedical CO.,LTD. - TWD -Infinity%
UnicoCell Biomed Co., Ltd. 68.23 Million TWD -417.277%
PELL Bio-Med Technology Co. Ltd. 147.46 Million TWD -139.355%